Difference between revisions of "Pimitespib (Jeselhy)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pimitespib NCI Drug Dictionary]: A specific inhibitor of heat shock protein...") |
|||
Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Gastrointestinal stromal tumor]]=== | ===[[Gastrointestinal stromal tumor]]=== | ||
− | #'''CHAPTER-GIST-301:''' Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2022 Jun 8:S0923-7534(22)01718-5. Epub ahead of print. [https://doi.org/10.1016/j.annonc.2022.05.518 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35688358/ PubMed] | + | #'''CHAPTER-GIST-301:''' Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2022 Jun 8:S0923-7534(22)01718-5. Epub ahead of print. [https://doi.org/10.1016/j.annonc.2022.05.518 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35688358/ PubMed] JapicCTI-184094 |
==Also known as== | ==Also known as== |
Revision as of 14:00, 6 September 2022
Mechanism of action
From the NCI Drug Dictionary: A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, Hsp90alpha/beta inhibitor TAS-116 specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta.
Preliminary data
Gastrointestinal stromal tumor
- CHAPTER-GIST-301: Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2022 Jun 8:S0923-7534(22)01718-5. Epub ahead of print. link to original article PubMed JapicCTI-184094
Also known as
- Code name: TAS-116